Surprising FDA Reversal Allows Sarepta to Resume Gene Therapy Treatment

On Monday afternoon, the FDA made a shocking reversal just a week after Sarepta pulled its Duchenne gene therapy from the market. The FDA has now given the green light for the company to start treating some patients again, a move that has left many in the biotech industry surprised and intrigued.

Interview with Baird Biotech Analyst Brian Skorney on Post-Hoc Live

Today on Post-Hoc Live, Baird biotech analyst Brian Skorney shared his insights on the recent developments with Sarepta. Skorney, who has been following Sarepta for years, discussed the implications of the FDA’s decision and what it means for the future of the company.

Skorney’s candid analysis of the last two volatile weeks and the potential impact on Sarepta’s reputation and market position is a must-watch for anyone interested in the biotech sector. His expertise sheds light on the challenges and opportunities facing Sarepta in the wake of this unexpected turn of events.

— Drew